Navigation Links
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Date:5/13/2008

require refrigeration and can be moved in and out of the refrigerator. In addition, NovoSeven(R) RT has a higher concentration for lower infusion volumes and quick administration. The needed infusion amount is almost half of that needed with the original NovoSeven(R).

NovoSeven(R) RT will be available in August 2008, and a new infusion kit with needle-free adapters will be offered separately. As a recombinant therapy, NovoSeven(R) RT is the only room temperature stable treatment for hemophilia with inhibitors that is not plasma-derived and, therefore, poses no risk of human viral transmission through its use.

About Hemophilia

Patients with hemophilia lack blood proteins essential for proper blood clotting. These patients fall into two categories depending on which blood protein, or factor, they are missing-people with hemophilia A (classic hemophilia) lack Factor VIII, while people with hemophilia B (also known as Christmas disease) lack Factor IX.

Hemophilia can range from mild to moderate or severe, depending on how much factor protein the body is lacking. In severe cases of hemophilia, factor deficiency can lead to spontaneous internal bleeding episodes or bleeding following an injury or surgery. To stop bleeding episodes and manage their disease, people with severe hemophilia infuse themselves with clotting factor therapy-Factor VIII or Factor IX-to replace their missing factor.

Inhibitors

Inhibitors are antibodies that develop and circulate in the bloodstream and neutralize clotting replacement Factor VIII or IX, causing bleeding to continue. Most inhibitors develop in the first nine to 50 days of factor- replacement therapy and are often diagnosed in young children. In rare cases, inhibitors can occur after years of treatment.

Treatment depends on the type of inhibitor. Patients with strong or high-responding inhibitors may be given bypassing agents, such as recombinant Factor VIIa or activated prothrombin comp
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
2. FDA Approves Health Claim for Brown Rice
3. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
4. FDA approves HeartMate II mechanical heart pump for heart-failure patients
5. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
6. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
9. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
10. VeriPrime Approves New Best Practices for Beef Production
11. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Hospital and MOSI officially announced a transformational partnership that will ... make a difference in the Tampa Bay community. Florida Hospital ... the support needed to keep the science center moving forward. ... Dome Theatre from film to a state-of-the-art digital 3D projection ... the state of Florida, and it is one of the ...
(Date:7/25/2014)... Diego, CA (PRWEB) July 25, 2014 AttorneyOne.com, ... all the latest information from the FDA on Ibuprofen ... July 21, that one lot of Ibuprofen and one lot ... recalled due to mislabeled packaging. Oxcarbazepine is used for ... epilepsy. , The reason for the recall is ...
(Date:7/25/2014)... July 25, 2014 A new study of ... of which are published today in Cancer , found ... and 74 who had an abnormal finding on a lung ... quality of life than did those who were screened and ... a surprise to the researchers. “We expected that participants with ...
(Date:7/25/2014)... 2014 This is a professional ... the Galactooligosaccharides (GOS) industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:7/25/2014)... (HealthDay News) -- Shift workers, especially men, may be at ... on such schedules, a new study suggests. Also at ... set schedule, with shifts moving around at various times of ... said one expert, Dr. Alan Manevitz, a clinical psychiatrist at ... long known that working shifts disrupts many key body chemicals, ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3
... Swanson got,leading scientists and researchers at the International ... natural rubber latex (NRL) yesterday,with insights into the ... Corporation. This commercially available NRL source,material has ultra ... desirable NRL properties in finished products., Vystar ...
... 2008 Elsevier and the Alzheimer,s ... Journal of the Alzheimer,s Association ( www.alzheimersanddementia.org ... MEDLINE (www.pubmed.gov) is the premier bibliographic database of ... the National Institutes of Health (NIH), MEDLINE contains ...
... Connecticut,Hospice, Inc., birthplace of Hospice in America, is ... from The Henrietta Szold-Hadassah-Hebrew,University School of Nursing, Jerusalem ... Nursing., Lauren Brown, MSN, Co-Director of Education, ... F. Pfriem International,Fellowship in Hospice and Palliative Nursing, ...
... the AHA-McKesson Quest for Quality Prize, ANN ARBOR, ... professionals of the University of Michigan Health,System provide some ... some of the safest, too. That,s according to the ... year,s lone finalist,for a major annual award., U-M ...
... HRC ) fiscal 2008 third quarter earnings release ... to participate in its,webcast the following morning on Thursday, ... Release: Hill-Rom Holdings, Inc.,s Fiscal 2008 Third Quarter,Earnings Release ... released to,the public after the NYSE close on Wednesday, ...
... Highlights:, - Record GAAP diluted EPS increased 34.2 percent to $0.51 from $0.38 in ... second-quarter 2007 - Record diluted EPS ... assets ... - Net revenues increased 15.6 percent to nearly $12.8 billion, - Specialty revenues ...
Cached Medicine News:Health News:Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing 2Health News:Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing 3Health News:Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing 4Health News:Alzheimer's & Dementia: The Journal of the Alzheimer's Association accepted for coverage in MEDLINE 2Health News:U-M Health System Honored by American Hospital Association for High Quality Care and Patient Safety 2Health News:U-M Health System Honored by American Hospital Association for High Quality Care and Patient Safety 3Health News:U-M Health System Honored by American Hospital Association for High Quality Care and Patient Safety 4Health News:Hill-Rom Holdings, Inc. Invites You to Join its Fiscal 2008 Third Quarter Earnings Webcast 2Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 2Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 3Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 4Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 5Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 6Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 7Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 8Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 9Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 10Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 11Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 12Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 13Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 14Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 15Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 16Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 17Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 18Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 19Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 20Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 21Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 22Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 23Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 24Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 25Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 26Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 27Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 28
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)...  AMETEK, Inc. (NYSE: AME ) today ... as Vice President and General Manager, Engineered Medical Components, ... "I am pleased that Kurt has joined ... experience, especially in the medical device industry, and we ... growth and success of our medical components businesses," commented ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2
... July 22, and OSAKA, Japan, July 23 ... Takeda Global Research & Development Center, Inc., a wholly ... U.S. Food and Drug Administration (FDA) that the FDA ... for the fixed-dose combination (FDC) of alogliptin and ACTOS((R)) ...
... , MENLO PARK, Calif., July 22 Apieron, ... positive coverage policy for the measurement of exhaled nitric oxide ... peer-reviewed evidence is sufficient to support benefit coverage for the ... the measurement of exhaled nitric oxide is considered medically necessary ...
Cached Medicine Technology:Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) 2Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) 3CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment 2
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... Combines BchiVac V-500, water-cooled secondary condenser ... housing Model V-500 is a powerful PTFE ... vacuum applications. Applications Ideally ... rotary evaporators Laboratory vacuum source ...
... secondary condenser to trap residual solvent vapors ... vacuum pump designed to handle most vacuum ... for use with up to two rotary ... instruments including vacuum ovens, concentrators, gel dryers, ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
Medicine Products: